Stifel Starts FibroGen (FGEN) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
UPDATE: RBC Capital Starts FibroGen (FGEN) at Outperform
December 9, 2014 7:39 AM EST(Updated - December 9, 2014 9:55 AM EST)
RBC Capital initiated coverage on FibroGen (NASDAQ: FGEN) with an Outperform rating and a price target of $38.00.
Analyst Michael J. Yee said, "We believe FGEN represents a compelling long-term opportunity with two multi-billion-dollar programs: 1) Novel Phase III anemia program with... More
Goldman Sachs Starts FibroGen (FGEN) at Buy
December 9, 2014 7:38 AM ESTGoldman Sachs initiates coverage on FibroGen (NASDAQ: FGEN) with a Buy rating and a price target of $32.00.
Analyst Terence Flynn said, "Based on the Roxa Phase 2 data we see three potential benefits over injectable ESAs potential to improve safety (focus will be on... More
William Blair Starts FibroGen (FGEN) at Outperform
December 8, 2014 7:42 AM ESTWilliam Blair initiated coverage on FibroGen (NASDAQ: FGEN) with an Outperform rating.
Analyst John Sonnier estimated that the company would generate revenue of $136 million in 2014 and $191 million in 2015, and believes the company has sufficient capital to sustain itself for at least two years.
"Our bullish investment outlook on FibroGen is based on a variety of factors," Sonnier said. "These include the strength of lead product candidates roxadustat, which is... More
